MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research

References

• Hanson G R, Rau K S, Fleckenstein A E. The methamphetamine experience: a NIDA partnership. Neuropharmacology 2004; 47(Suppl. 1)92–100
   PubMedGoogle Scholar
• Sulzer D, Sonders M S, Poulsen N W, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75: 406–433
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. Ecstasy and Amphetamines: Global Survey 2003. UNODC, Vienna 2003
   Google Scholar
• Hart C L, Ward A S, Haney M, Foltin R W, Fischman M W. Methamphetamine self-administration by humans. Psychopharmacology (Berl) 2001; 157: 75–81
   PubMed Web of Science ®Google Scholar
• McKetin R, McLaren J, Kelly E. The Sydney methamphetamine market: patterns of supply, use, personal harms and social consequences: National Drug and Alcohol Research Centre. Commonwealth of Australia, University of New South Wales 2005
   Google Scholar
• Meredith C W, Jaffe C, Ang-Lee K, Saxon A J. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13: 141–154
   PubMed Web of Science ®Google Scholar
• Baumann M H, Wang X, Rothman R B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189: 407–424
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 2006; 20: 188–193
   PubMed Web of Science ®Google Scholar
• Barrett S P, Gross S R, Garand I, Pihl R O. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 2005; 40: 1525–1537
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Agaliotis M, White B, Stafford J. New South Wales Party Drug Trends 2004: Findings from the Party Drugs Initiative (PDI). National Drug and Alcohol Research Centre, University of New South Wales, Sydney 2005
   Google Scholar
• Kalasinsky K S, Hugel J, Kish S J. Use of MDA (the ‘love drug’) and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 2004; 49: 1106–1112
   PubMed Web of Science ®Google Scholar
• Rothman R B, Baumann M H, Dersch C M, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39: 32–41
   PubMed Web of Science ®Google Scholar
• Fitzgerald J L, Reid J J. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 313–323
   PubMedGoogle Scholar
• Tatsuta T, Kitanaka N, Kitanaka J, Morita Y, Takemura M. Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats. Neurochem Res 2005; 30: 1377–1385
   PubMedGoogle Scholar
• Parrott A C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005; 19: 71–83
   PubMed Web of Science ®Google Scholar
• Liechti M E, Vollenweider F X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001; 16: 589–598
   PubMed Web of Science ®Google Scholar
• Newton T F, Roache J D, De La Garza R, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2000; 631: 1537–1544
   Google Scholar
• Shearer J, Gowing L R. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004; 23: 203–211
   PubMed Web of Science ®Google Scholar
• Vocci F J, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005; 18: 265–270
   PubMedGoogle Scholar
• Beardsley P M, Balster R L, Harris L S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 1986; 18: 149–157
   PubMedGoogle Scholar
• Schenk S, Gittings D, Johnstone M, Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 2003; 169: 21–27
   PubMedGoogle Scholar
• Cornish J L, Shahnawaz Z, Thompson M R, et al. Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 2003; 482: 339–341
   PubMedGoogle Scholar
• Carney J M, Landrum R W, Cheng M S, Seale T W. Establishment of chronic intravenous drug self-administration in the C57BL/6J mouse. Neuroreport 1991; 2: 477–480
   PubMedGoogle Scholar
• Ranaldi R, Poeggel K. Baclofen decreases methamphetamine self-administration in rats. Neuroreport 2002; 13: 1107–1110
   PubMed Web of Science ®Google Scholar
• Ranaldi R, Anderson K G, Carroll F I, Woolverton W L. Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine. Psychopharmacology (Berl) 2000; 153: 103–110
   PubMedGoogle Scholar
• Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 2004; 1021: 272–276
   PubMed Web of Science ®Google Scholar
• Davidson C, Lee T H, Ellinwood E H. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int 2005; 46: 189–203
   PubMedGoogle Scholar
• Clemens K J, Cornish J L, Hunt G E, McGregor I S. Intravenous methametamine self-administration in rats: effects of intravenous or intraperitoneal MDMA coadministration. Pharmacol Biochem Behav 2006, Nov 14 [Epub ahead of print]
   PubMedGoogle Scholar
• Munzar P, Baumann M H, Shoaib M, Goldberg S R. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology (Berl) 1999; 141: 287–296
   PubMedGoogle Scholar
• Piasecki M P, Steinagel G M, Thienhaus O J, Kohlenberg B S. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs 2002; 34: 301–304
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Barker B, Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 2004; 99: 187–195
   PubMed Web of Science ®Google Scholar
• Robledo P, Balerio G, Berrendero F, Maldonado R. Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 338–349
   PubMedGoogle Scholar
• Morley K C, Arnold J C, McGregor I S. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 648–657
   PubMedGoogle Scholar
• Stephenson C P, Hunt G E, Topple A N, McGregor I S. The distribution of 3,4-methylenedioxymethamphetamine ‘Ecstasy’-induced c-fos expression in rat brain. Neuroscience 1999; 92: 1011–1023
   PubMedGoogle Scholar
• Wolff K, Tsapakis E M, Winstock A R, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 2006; 20: 400–410
   PubMedGoogle Scholar
• Battaglia G, Yeh S Y, De Souza E B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988; 29: 269–274
   PubMed Web of Science ®Google Scholar
• Sprague J E, Everman S L, Nichols D E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1998; 19: 427–441
   PubMed Web of Science ®Google Scholar
• McGregor I S, Clemens K J, Van Der Plasse G, et al. Increased anxiety 3 months after brief exposure to MDMA (‘Ecstasy’ in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 2003; 28: 1472–1484
   PubMedGoogle Scholar
• Morley K C, Gallate J E, Hunt G E, Mallet P E, McGregor I S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (‘ecstasy’). Eur J Pharmacol 2001; 433: 91–99
   PubMed Web of Science ®Google Scholar
• Johnson M, Hanson G R, Gibb J W. Effects of dopaminergic and serotonergic receptor blockade on neurochemical changes induced by acute administration of methamphetamine and 3,4-methylenedioxymethamphetamine. Neuropharmacology 1988; 27: 1089–1096
   PubMedGoogle Scholar
• Kokoshka J M, Metzger R R, Wilkins D G, Gibb J W, Hanson G R, Fleckenstein A E. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res 1998; 799: 78–83
   PubMedGoogle Scholar
• Cadet J L, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003; 17: 1775–1788
   PubMed Web of Science ®Google Scholar
• Cadet J L, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 2005; 8: 199–206
   PubMed Web of Science ®Google Scholar
• Abekawa T, Ohmori T, Honda M, Ito K, Koyama T. Effect of low doses of L-NAME on methamphetamine-induced dopaminergic depletion in the rat striatum. J Neural Transm 2001; 108: 1219–1230
   PubMedGoogle Scholar
• Cappon G D, Morford L L, Vorhees C V. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res Dev Brain Res 1997; 103: 155–162
   PubMedGoogle Scholar
• Villemagne V, Yuan J, Wong D F, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998; 18: 419–427
   PubMed Web of Science ®Google Scholar
• Pubill D, Canudas A M, Pallas M, Camins A, Camarasa J, Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 490–499
   PubMed Web of Science ®Google Scholar
• Imam S Z, Ali S F. Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J Neurochem 2001; 78: 952–959
   PubMedGoogle Scholar
• Burrows K B, Gudelsky G, Yamamoto B K. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 2000; 398: 11–18
   PubMed Web of Science ®Google Scholar
• Clemens K J, Cornish J L, Li K M, Hunt G E, McGregor I S. MDMA (‘Ecstasy’) and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 2005; 49: 195–207
   PubMed Web of Science ®Google Scholar
• Clemens K J, Van Nieuwenhuyzen P S, Li K M, Cornish J L, Hunt G E, McGregor I S. MDMA (‘ecstasy’), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 2004; 173: 318–325
   PubMed Web of Science ®Google Scholar
• Bull E J, Hutson P H, Fone K C. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT(2A) receptor responsivity. Neuropharmacology 2004; 46: 202–210
   PubMedGoogle Scholar
• McGregor I S, Gurtman C G, Morley K C, et al. Increased anxiety and ‘depressive’ symptoms months after MDMA (‘ecstasy’) in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 2003; 168: 465–474
   PubMedGoogle Scholar
• Williams M T, Morford L L, Wood S L, et al. Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 2003; 968: 89–101
   PubMedGoogle Scholar
• Broening H W, Morford L L, Inman-Wood S L, Fukumura M, Vorhees C V. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 2001; 21: 3228–3235
   PubMed Web of Science ®Google Scholar
• Timar J, Gyarmati S, Szabo A, Furst S. Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav Pharmacol 2003; 14: 199–206
   PubMedGoogle Scholar
• Byrne T, Baker L E, Poling A. MDMA and learning: effects of acute and neurotoxic exposure in the rat. Pharmacol Biochem Behav 2000; 66: 501–508
   PubMedGoogle Scholar
• Bisagno V, Ferguson D, Luine V N. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 2002; 940: 95–101
   PubMed Web of Science ®Google Scholar
• Chapman D E, Hanson G R, Kesner R P, Keefe K A. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther 2001; 296: 520–527
   PubMed Web of Science ®Google Scholar
• Friedman S D, Castaneda E, Hodge G K. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1998; 61: 35–44
   PubMedGoogle Scholar
• Guillot C, Greenway D. Recreational ecstasy use and depression. J Psychopharmacol 2006; 20: 411–416
   PubMed Web of Science ®Google Scholar
• Parrott A C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006; 20: 147–163
   PubMed Web of Science ®Google Scholar
• Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006; 20: 211–225
   PubMed Web of Science ®Google Scholar
• London E D, Berman S M, Voytek B, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 2005; 58: 770–778
   PubMed Web of Science ®Google Scholar
• Chang L, Cloak C, Patterson K, Grob C, Miller E N, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 2005; 57: 967–974
   PubMed Web of Science ®Google Scholar
• Chang L, Ernst T, Speck O, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002; 114: 65–79
   PubMed Web of Science ®Google Scholar
• Thompson P M, Hayashi K M, Simon S L, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004; 24: 6028–6036
   PubMed Web of Science ®Google Scholar
• Gurtman C G, Morley K C, Li K M, Hunt G E, McGregor I S. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 2002; 446: 89–96
   PubMedGoogle Scholar
• Mechan A O, Esteban B, O'Shea E, Elliott J M, Colado M I, Green A R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. Br J Pharmacol 2002; 135: 170–180
   PubMed Web of Science ®Google Scholar
• Clemens K J, Cornish J L, Hunt G E, McGregor I S. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 2007; 86: 183–190
   PubMed Web of Science ®Google Scholar